Search
Pentobarbital
go.drugbank.com/drugs/DB00312ApprovedVet approvedIt is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. … A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally.
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedIt has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.
Tedizolid
go.drugbank.com/drugs/DB14569ApprovedInvestigational[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Cinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The ...
Technetium Tc-99m sestamibi
go.drugbank.com/drugs/DB09161ApprovedInvestigationalThe mechanism by which sestamibi localizes to these tissues has not been established. … Following intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by the myocardium, parathyroid, and/or breast tissue.
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigational[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.
Lopinavir
go.drugbank.com/drugs/DB01601ApprovedInvestigational[saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself … [A191757] Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.[L12012]
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawnIn 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied the manufacturing procedures of Zotepine tablets in Germany, but the status remained inactive. … [A31857] Zotepine was never approved by the FDA.
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]
Bucetin
go.drugbank.com/drugs/DB13278ApprovedWithdrawnBucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]